Delcath Systems Inc.

NASDAQ: DCTH · Real-Time Price · USD
16.35
-0.52 (-3.08%)
At close: Jun 06, 2025, 3:59 PM
16.38
0.18%
After-hours: Jun 06, 2025, 04:04 PM EDT

Company Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.

It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.

Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Delcath Systems Inc.
Delcath Systems Inc. logo
Country United States
IPO Date May 3, 2018
Industry Medical - Specialties
Sector Healthcare
Employees 96
CEO Gerard J. Michel MBA, MS

Contact Details

Address:
1633 Broadway
New York City, New York
United States
Website https://www.delcath.com

Stock Details

Ticker Symbol DCTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000872912
CUSIP Number 24661P807
ISIN Number US24661P8077
Employer ID 06-1245881
SIC Code 3841

Key Executives

Name Position
Gerard J. Michel MBA, MS Chief Executive Officer & Director
Dr. Martha S. Rook Ph.D. Chief Operating Officer
Sandra Pennell CPA Chief Financial Officer
David Hoffman J.D. General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. Johnny John M.D. Senior Vice President of Clinical Operations & Medical Affairs
Dr. Michael Brunner M.D. Senior Vice President of Interventional Oncology
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 22, 2025 8-K Current Report
May 19, 2025 4 Filing
May 19, 2025 4 Filing
May 19, 2025 4 Filing
May 19, 2025 4 Filing
May 19, 2025 4 Filing
May 16, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 12, 2025 SCHEDULE 13D/A [Amend] Filing
May 09, 2025 4 Filing